TNYA Tenaya Therapeutics, Inc.
Listings ·
Nasdaq told Tenaya Therapeutics on January 28, 2026 that its shares had closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until July 27, 2026 to regain compliance, and an 8-K filed January 30 also adds 2,161,000 shares to its inducement equity plan.
Tenaya has until October 13, 2025 to regain compliance, and may get another 180 days if it moves to the Nasdaq Capital Market.
Tenaya priced 75,000,000 units at $0.70 for about $52.5 million, with two warrant series attached to each unit. Its lead gene therapies are in early trials with only a few patients dosed, and the stock's last reported sale price on the pricing day was $0.9469.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $68.6 million | $86.7 million |
| Net income (loss) | -$90.6 million | -$111.1 million |
| Cash from operations | -$68.3 million | -$90.5 million |
| Cash and equivalents | $100.5 million | $4.3 million |
| Short-term investments | $57.1 million |
Our latest story on this, dated Mar 3, 2025: "Tenaya Therapeutics prices $52.5 million offering of 75,000,000 units at $0.70". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 18, 2025: "Tenaya Therapeutics gets Nasdaq notice for trading below $1.00". The story links the filing or release it is based on. Read the story.
Tenaya Therapeutics, Inc. trades under the ticker TNYA on NASDAQ.
Tenaya Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Tenaya Therapeutics, Inc. is 1858848. Its filings are on SEC EDGAR.
224,230,012 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-05.
Our directory records Tenaya Therapeutics, Inc. under United States.
Our directory classifies Tenaya Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Tenaya Therapeutics, Inc. is US87990A1060.
aibio.space lists Tenaya Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Tenaya Therapeutics, Inc. reported a net loss of $90.6 million for the fiscal year ended Dec 31, 2025, and used $68.3 million of cash in operations, per its annual report to the SEC.
$68.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
$78.1 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Tenaya Therapeutics, dated Jan 30, 2026: "Tenaya Therapeutics gets Nasdaq minimum bid price notice, has until July 27, 2026". Nasdaq told Tenaya Therapeutics on January 28, 2026 that its shares had closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until July 27, 2026 to regain compliance, and an 8-K filed January 30 also adds 2,161,000 shares to its inducement equity plan. Source.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio